Page last updated: 2024-09-02

n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide and Benign Neoplasms

n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide has been researched along with Benign Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (83.33)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Price, PM; Saleem, A1
Baguley, BC; Brady, F; Brown, G; Denny, WA; Harte, RJ; Jones, T; Luthra, SK; Osman, S; Price, PM1
Baguley, BC; Brady, F; Brown, G; Denny, WA; Harte, RJ; Hume, SP; Jones, T; Luthra, SK; Matthews, JC; Osman, S; Price, PM1
Baguley, BC; Evans, BD; Harvey, VJ; McCrystal, MR; Porter, DJ; Thompson, PI1
Baguley, BC; Dunlop, IC; Evans, BD; Gamage, RS; Kestell, P; McCrystal, MR; Paxton, JW1
Baguley, BC; Evans, BD; Kestell, P; McCrystal, MR; Paxton, JW; Robertson, IG; Schofield, PC1

Trials

5 trial(s) available for n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide and Benign Neoplasms

ArticleYear
Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 1997, Volume: 48, Issue:4

    Topics: Acridines; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carbon Radioisotopes; Dose-Response Relationship, Drug; Female; Humans; Isotope Labeling; Male; Middle Aged; Neoplasms; Tomography, Emission-Computed

1997
Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
    Cancer research, 1997, Jun-01, Volume: 57, Issue:11

    Topics: Acridines; Adult; Aged; Animals; Antineoplastic Agents; Brain; Chromatography, High Pressure Liquid; Female; Humans; Kidney; Liver; Lung; Male; Middle Aged; Myocardium; Neoplasms; Plasma; Rats; Rats, Sprague-Dawley; Tomography, Emission-Computed

1997
Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:1

    Topics: Acridines; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Facial Pain; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms

1999
Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:1

    Topics: Acridines; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms

1999
Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:1

    Topics: Acridines; Adult; Aged; Antineoplastic Agents; Biotransformation; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms

1999

Other Studies

1 other study(ies) available for n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide and Benign Neoplasms

ArticleYear
Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-15, Volume: 14, Issue:24

    Topics: Acridines; Antineoplastic Agents; Area Under Curve; Fluorouracil; Humans; Neoplasms; Solubility

2008